Loading…
Sana Biotechnology, Inc. is projected to rise to $4.31 by 2027, a +10% move from its current price of $3.93. SANA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.80 | $3.93 | $4.07 | 0.00% |
| Jul 14 | $3.74 | $3.93 | $4.13 | 0.00% |
| Jul 15 | $3.70 | $3.93 | $4.18 | 0.00% |
| Jul 16 | $3.66 | $3.93 | $4.21 | +0.01% |
| Jul 17 | $3.63 | $3.93 | $4.25 | +0.01% |
| Jul 18 | $3.61 | $3.93 | $4.28 | +0.01% |
| Jul 19 | $3.58 | $3.93 | $4.31 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.58 | $3.93 | $4.31 | +0.01% |
| Week 2 | $3.45 | $3.93 | $4.48 | +0.02% |
| Week 3 | $3.35 | $3.93 | $4.61 | +0.03% |
| Week 4 | $3.27 | $3.93 | $4.73 | +0.04% |
| Week 5 | $3.20 | $3.93 | $4.83 | +0.05% |
| Week 6 | $3.14 | $3.93 | $4.93 | +0.06% |
| Week 7 | $3.08 | $3.93 | $5.02 | +0.07% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sana Biotechnology, Inc. is a biotechnology company that focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.
The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc.
in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Sana Biotechnology, Inc. (SANA) is a healthcare company focused on biotechnology. The stock trades as SANA and is currently priced at $4.01 with a market capitalization of $1.12B, and is ranked 2420 by market position.
The near-term forecast shows a neutral stance in 2026 with an average price near the current level, while the longer-term outlook shifts to a bullish trajectory with substantial upside into the 2030s and beyond. The price path envisions higher-average levels in the latter half of the decade and into 2050, albeit with the usual caveats about estimates and uncertainty.
A major floor 46.3% below — a decisive break under it would weaken the trend.
The nearest floor, 31.8% below — buyers have tended to step in here.
The nearest ceiling, 4.8% above — a clean break opens room to run.
A major ceiling 27.0% above — clearing it would confirm fresh momentum.
Key SANA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SANA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.97 | Sell | $3.89 | Buy |
| MA 10 | $3.78 | Buy | $3.77 | Buy |
| MA 20 | $3.42 | Buy | $3.56 | Buy |
| MA 50 | $3.27 | Buy | $3.38 | Buy |
| MA 100 | $3.35 | Buy | $3.45 | Buy |
| MA 200 | $3.87 | Buy | $3.57 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.62 | Neutral |
| Stoch RSI (14) | 34.87 | Neutral |
| CCI (20) | 79.98 | Neutral |
| Williams %R (14) | -31.40 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 14.93 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 68.60 | Neutral |
| TRIX (15) | 0.75 | Buy |
| Awesome (5,34) | 0.72 | Buy |
| Ultimate (7,14,28) | 68.39 | Neutral |
| Momentum (10) | 0.59 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 4.04 | Sell |
| ADX (14) | 27.34 | Buy |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is NEUTRAL. The RSI14 is 80, indicating a heated short-term momentum, while the 50-day moving average sits at $3.21 and the 200-day moving average at $3.85. A clear resistance stands at $4.01 and a support level sits at $2.68.
The stock’s 30-day trading range stretches from $3.10 to $5.18, outlining a band within which price action has fluctuated recently.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.68 | $3.93 | $5.25 | 0% | Neutral | |
| $3.34 | $4.31 | $5.92 | +10% | Neutral | |
| $3.20 | $4.28 | $6.16 | +9% | Neutral | |
| $3.04 | $4.20 | $6.26 | +7% | Neutral | |
| $3.38 | $4.79 | $7.37 | +22% | Bullish | |
| $3.82 | $5.55 | $8.75 | +41% | Bullish | |
| $4.33 | $6.45 | $10.41 | +64% | Bullish | |
| $4.64 | $7.06 | $11.63 | +80% | Bullish | |
| $4.41 | $6.86 | $11.51 | +75% | Bullish | |
| $4.64 | $7.36 | $12.57 | +87% | Bullish | |
| $6.07 | $10.58 | $19.43 | +169% | Bullish | |
| $8.49 | $17.51 | $35.74 | +346% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.68 | $3.93 | $4.60 | +0.00% |
| August 2026 | $3.25 | $3.87 | $4.75 | -1.59% |
| September 2026 | $3.28 | $3.93 | $4.90 | +1.74% |
| October 2026 | $3.18 | $3.85 | $4.85 | -2.18% |
| November 2026 | $3.18 | $3.87 | $4.92 | +0.61% |
| December 2026 | $3.34 | $4.10 | $5.25 | +5.77% |
Click any year to see its month-by-month SANA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Sana Biotechnology, Inc.'s 2026 outlook centres on $3.93, within a $2.68 to $5.25 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, SANA could reach as high as $5.92, with a base case around $4.31 and support toward $3.34 — roughly +10% from $3.93. A consolidation phase looks the most probable path here.
Expect SANA to range from $3.20 to $6.16 through 2028. The $4.28 average target implies a +9% move from current prices. That is -1% versus the projected 2027 average. Price action looks broadly range-bound.
The SANA price prediction for 2029 points to an average of $4.20 (low $3.04, high $6.26) — a potential gain of +7% on today's $3.93. A consolidation phase looks the most probable path here.
In 2030, SANA is projected to trade between $3.38 and $7.37, averaging $4.79 — a potential gain of +22% from today's $3.93. That is up +14% on the projected 2029 average. Momentum favours further upside here.
Sana Biotechnology, Inc.'s 2031 outlook centres on $5.55, within a $3.82 to $8.75 range. That is up +16% on the projected 2030 average. That marks a +41% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, SANA could reach as high as $10.41, with a base case around $6.45 and support toward $4.33 — roughly +64% from $3.93. Momentum favours further upside here.
Expect SANA to range from $4.64 to $11.63 through 2033. The $7.06 average target implies a +80% move from current prices. That is up +9% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The SANA price prediction for 2034 points to an average of $6.86 (low $4.41, high $11.51) — a potential gain of +75% on today's $3.93. Momentum favours further upside here.
In 2035, SANA is projected to trade between $4.64 and $12.57, averaging $7.36 — a potential gain of +87% from today's $3.93. That is up +7% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Sana Biotechnology, Inc.'s 2040 outlook centres on $10.58, within a $6.07 to $19.43 range. That is up +44% on the projected 2035 average. That marks a +169% change versus current levels. Momentum favours further upside here.
By 2050, SANA could reach as high as $35.74, with a base case around $17.51 and support toward $8.49 — roughly +346% from $3.93. Buyers look set to stay in control over this stretch.
Investing $1,000 in SANA today (≈ 254.452926 SANA) could be worth
$4,456.27
+$3,456.27 (+346%) by 2050 · US Dollar
Based on the average projected SANA price of $17.51 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SANAwould be worth at today's price.
$1,000 invested in SANA on Jul 10, 2025 (≈ 246.305422 SANA) would be worth
$967.98
-$32.02 (-3.2%) today · 0.97× · US Dollar
Based on a SANA entry price of $4.06 vs. today's $3.93.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.01 | $980.05 | -2.0% |
| 1 month ago | $2.82 | $1,393.62 | +39.4% |
| 3 months ago | $3.09 | $1,271.84 | +27.2% |
| 6 months ago | $4.58 | $858.08 | -14.2% |
| 1 year ago | $4.06 | $967.98 | -3.2% |
| All time (5.0y) ago | $17.72 | $221.78 | -77.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SANA forecast.
Our base-case forecast reaches $7.90 around 2040.
Implied market cap at $7.90: $2.2B
The multi-year forecast points to a bullish shift beginning in 2030. The 2030 forecast documents a $4.89 average price with a $3.35–$7.73 range and a 21.9% ROI, signaling a bullish stance. The 2031 forecast shows an average of $5.87 (min $3.91, max $9.53) with a 46.3% ROI, followed by 2032 at an average of $6.81 (min $4.42, max $11.34) and a 69.8% ROI.
By 2033 the average is $7.38 (min $4.67, max $12.56) with an 84% ROI, and 2034 shows $7.26 (min $4.48, max $12.61) with an 81% ROI; 2035 carries an average of $7.72 (min $4.66, max $13.67) and a 92.6% ROI. The forecast continues bullish into 2040 with an average of $11.26 (min $6.08, max $21.56) and a 180.9% ROI, and by 2050 an average of $18.70 (min $8.41, max $40.02) with a 366.2% ROI. These are estimates and not guarantees, but the long-run trajectory points to meaningful upside under the forecast.
Tap a question to reveal the answer.
Avg $4.89; min $3.35; max $7.73; ROI 21.9%; sentiment BULLISH. These are estimates, not guarantees.
Near-term forecasts for 2026 are NEUTRAL with avg $4.01 (min $2.68, max $5.51; ROI 0%). From 2030 onward the outlook is BULLISH with higher averages and ROIs (e.g., 2031 ROI 46.3%, 2040 ROI 180.9%, 2050 ROI 366.2%). These are estimates, not guarantees.
The 2050 max forecast is $40.02, indicating a potential to approach that level within the forecast horizon. These are estimates, not guarantees.
Current price is $4.01 and market cap is $1.12B. These are the current figures provided.
Avg $5.87; min $3.91; max $9.53; ROI 46.3%; sentiment BULLISH. These are estimates, not guarantees.
Sana Biotechnology, Inc. Community Discussion
0Share your Sana Biotechnology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.